Company Profile

Checkmate Pharmaceuticals, Inc. is a clinical stage biotechnology company focused on developing its proprietary technology to harness the power of the immune system to combat cancer. The Company's product candidate, vidutolimod (CMP-001), is an advanced generation Toll-like receptor 9 (TLR9) agonist, delivered as a biologic virus-like particle (VLP) utilizing a CpG-A oligodeoxynucleotide as a key component, designed to trigger the body's innate immune system to attack tumors in combination with other therapies. The Company is conducting a Phase II trial of vidutolimod in combination with nivolumab (OPDIVO), in anti-PD-1 refractory melanoma. The Company is also conducting a randomized Phase II/III trial of vidutolimod in combination with nivolumab in first-line melanoma. The Company's VLP technology is designed to encapsulate and protect the CpG-A oligonucleotide from degradation in the tumor.

Employees

Sector

Biotechnology & Medical Research

More about the company

02/06/22	Regeneron Completes Checkmate Pharmaceuticals Deal, Triggers $5 Million Milestone Payment to Kuros Biosciences	MT
02/06/22	Kuros To Receive $5 Million Milestone Payment from Regeneron's Acquisition Of Checkmate	MT
31/05/22	Checkmate Pharmaceuticals, Inc. Appoints Robert E. Landry as Chief Financial Officer	CI
31/05/22	Checkmate Pharmaceuticals, Inc. Announces Board Changes	CI
31/05/22	Checkmate Pharmaceuticals, Inc.(NasdaqGM:CMPI) dropped from NASDAQ Composite Index	CI
31/05/22	Checkmate Pharmaceuticals, Inc.(NasdaqGM:CMPI) dropped from S&P TMI Index	CI
27/05/22	Regeneron Pharmaceuticals, Inc. completed the acquisition of Checkmate Pharmaceuticals, Inc. from Decheng Capital China Life Sciences USD Fund III, L.P., a fund managed by Decheng Capital LLC, Arthur Krieg and others.	CI
27/05/22	University of Iowa Holden Comprehensive Cancer Center Presents Preliminary Data from Clinical Trial of Vidutolimod at the 2022 American Society of Clinical Oncology Annual Meeting	CI
12/05/22	Checkmate Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	CI
27/04/22	Kuros Biosciences' Q1 Medical Devices Sales Surge 102% Following US FDA Approval For MagnetOs	MT
20/04/22	BTIG Downgrades Checkmate Pharmaceuticals to Neutral From Buy	MT
19/04/22	Sector Update: Health Care Stocks Carried Higher in Rising Tuesday Markets	MT
19/04/22	Top Midday Gainers	MT

20/04/22	BTIG Downgrades Checkmate Pharmaceuticals to Neutral From Buy	MT
30/03/22	BTIG Adjusts Checkmate Pharmaceuticals' Price Target to $9 from $29, Keeps Buy Rating	MT
06/10/21	CHECKMATE PHARMACEUTICALS : BofA Securities Upgrades Checkmate Pharmaceuticals to Buy From Neutral, Price Target at $7	MT

02/06/22	Kuros Biosciences: Completion of the Acquisition of Checkmate Pharmaceuticals by Regeneron Pharmaceuticals Triggers a $5 Million Milestone Payment	AQ
31/05/22	Checkmate Pharmaceuticals : Completion of Acquisition or Disposition of Assets - Form 8-K	PU
31/05/22	CHECKMATE PHARMACEUTICALS, INC. : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	AQ
27/05/22	University of Iowa Holden Comprehensive Cancer Center Presents Preliminary Data from Clinical Trial of Vidutolimod at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting	AQ
27/05/22	University of Iowa Holden Comprehensive Cancer Center Presents Preliminary Data from Clinical Trial of Vidutolimod at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting	GL

02/06/22	Bourse Zurich: rebond technique, le SMI finit au-dessus des 11'500 points
02/06/22	Bourse Zurich: dans le vert, à la faveur d'un rebond technique
02/06/22	Kuros reçoit un paiement d'étapes après la cession de Checkmate
02/06/22	Kuros erhält durch Checkmate-Übernahme Meilensteinzahlung von 5 Mio USD
16/03/22	Kuros Biosciences double ses revenus issus des produits en 2021

Manager	Title	Age	Since
Barry A. Labinger CEO	Chief Executive Officer	62	12/12/2018
Robert Landry DFI	Director of Finance/CFO	62	31/05/2022
James Wooldridge CTO	Chief Tech/Sci/R&D Officer	60	01/10/2019

Checkmate Pharmaceuticals, Inc. Stock

Stocks

CMPI

US1628181083

Biotechnology & Medical Research

Latest news : Checkmate Pharmaceuticals, Inc.

Analysts' recommendations: Checkmate Pharmaceuticals, Inc.

Press Releases: Checkmate Pharmaceuticals, Inc.

News in other languages: Checkmate Pharmaceuticals, Inc.

Managers and Directors: Checkmate Pharmaceuticals, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Company Profile

Date	Insider	Type	Main position	Quantity	% Market Cap.
31/05/22	Alan Fuhrman	Issuer sale	Chief Executive Officer	279,437	1.2919%
31/05/22	Robert Dolski	Issuer sale	Chief Financial Officer	278,480	1.2874%
31/05/22	Alan Bash	Issuer sale	Chief Executive Officer	575,000	2.6583%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CHECKMATE PHARMACEUTICALS, INC.	-.--%	+0.38%	-	-	231M
ARGENX SE	+1.03%	+7.52%	+54.74%	+114.98%	55.58B
WUXI APPTEC CO., LTD.	+2.72%	+3.06%	+53.28%	+47.85%	43.47B
BIONTECH SE	+1.04%	+2.59%	-13.88%	-17.70%	22.64B
INSMED INCORPORATED	+1.16%	+4.22%	+1.36%	+403.59%	20.96B
WUXI BIOLOGICS (CAYMAN) INC.	+3.81%	-4.13%	+16.62%	-30.70%	15.79B
GENMAB A/S	+0.15%	+0.50%	+9.10%	-40.04%	15.3B
EXELIXIS, INC.	-0.61%	+0.85%	+27.21%	+178.42%	13.45B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+5.27%	+6.41%	+21.05%	-	11.74B
PHARMAESSENTIA CORPORATION	+1.61%	+1.17%	+90.79%	+212.97%	10.96B
Average	+1.61%	+0.26%	+28.92%	+108.67%	23.32B
Weighted average by Cap.	+1.69%	+1.60%	+33.75%	+101.77%